Press Release FOR IMMEDIATE RELEASE CRITICAL OUTCOME TECHNOLOGIES INC. INITIATES PRECLINICAL TESTING OF AML DRUG CANDIDATES London, Ontario (January 24, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that it has completed synthesis of compounds from its acute myelogenous leukemia (AML) program and has initiated confirmatory preclinical tests, representing an important step forward in the development of these potential drug candidates.

"We are delighted that we have achieved this key milestone in our AML program," said Dr. Wayne Danter, CEO. "The successful synthesis and initiation of the preclinical evaluation of the first candidates from our third major drug discovery program provides further validation of CHEMSAS® as a powerful artificial intelligence drug discovery engine. Successful candidates from this program will provide additional valuable commercial assets that can be licensed to partners for further development."
Like many other cancers, AML is the result of multiple gene mutations that affect multiple cell signaling kinase pathways. With few exceptions, traditional therapies that target a single abnormal kinase have produced disappointing long